Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate‐to‐severe psoriasis: a pooled analysis of two randomized controlled trials

Benzer Materyaller

• Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from the CLEAR study
  Yazar:: Blauvelt, A., ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Certolizumab pegol for the treatment of patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials
  Yazar:: Blauvelt, A., ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE)
  Yazar:: Reich, K., ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• Incidence of serious gastrointestinal events among tildrakizumab‐treated patients with psoriasis: Letter to the Editor
  Yazar:: Gooderham, M., ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks
  Yazar:: Reich, K., ve diğerleri
  Baskı/Yayın Bilgisi: (2019)